Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
about
Steroidal contraceptives: effect on bone fractures in womenEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenNatural Products from Chinese Medicines with Potential Benefits to Bone HealthTeriparatide for osteoporosis: importance of the full courseManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchPINP as a biological response marker during teriparatide treatment for osteoporosisBisphosphonate drug holiday: choosing appropriate candidatesBone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practiceNovel biological markers of bone: from bone metabolism to bone physiologyBone turnover markers: Emerging tool in the management of osteoporosisChanges in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.An overview and management of osteoporosisDenosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.Dried Plums, Prunes and Bone Health: A Comprehensive Review.Identification of Osteoporosis-Associated Protein Biomarkers from Ovariectomized Rat UrineHigher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis.Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 yearsRandomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.Osteoporosis, fractures, and diabetes.Effect of chronic activity-based therapy on bone mineral density and bone turnover in persons with spinal cord injuryProspective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.Prevalence of vitamin D insufficiency and low bone mineral density in elderly Thai nursing home residents.Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS).Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density.Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in Pomerania.Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards: osteoporos int 2011;22:391-420.Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.Harmonised Australian Reference Intervals for Serum PINP and CTX in AdultsComparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture.The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women.Evaluation of a topical herbal agent for the promotion of bone healing.Expressions and clinical significance of serum bone Gla-protein, bone alkaline phosphatase and C-terminal telopeptide of type I collagen in bone metabolism of patients with osteoporosisBone remodeling markers and bone metastases: From cancer research to clinical implicationsFracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).
P2860
Q24193793-0C0CD94E-639D-4ADA-A332-75B8AD41C6F6Q24612411-6CCEB8B4-E057-4497-8895-39E45BAB9274Q26765485-F14284DC-808F-4BAE-B338-C444E0611987Q26768410-F282AD57-CB34-4972-984E-3217B8ED287CQ26782621-884B2CD3-7898-4354-A446-2775237A4993Q26859267-C5766FDB-45C3-4EE8-9381-85DEBE0C1657Q27004682-708DDBFA-78C8-4C15-AF22-7A1818FC144DQ28066185-40AB7810-C1AA-410B-AEB6-F547278A86DFQ28067712-C552DE04-AF92-45EF-A541-5C99D5831ECCQ28074551-521926CF-20CB-46A5-96C4-894954A4CBB6Q28728374-BCD9FF55-E708-416F-9318-BAD262452D69Q30235173-3B4829C1-C2DE-400F-BD39-978E6E1F2700Q30235274-31AA8EB6-2EB2-463E-8352-2AD0684123E4Q30978614-8AF04670-85FE-4E01-BBC7-5574478EE2E4Q31065032-D8FF29C8-569B-4E0E-8EDB-BD0106C7EB76Q33570135-9EB9A7C1-7462-4D88-9D7D-AB59272807DFQ33572610-1E8A7F8E-9DF4-4D70-9515-278A9DBA1029Q33616951-049D6A49-5B6C-41A6-BD74-698AF470DCACQ33668643-112B5BA0-4CF3-4CA4-ACF9-C27EEE4260DBQ33740351-C6DBF1A1-416A-4CCD-BDD5-968967EFE5B6Q33811677-54367D96-2A71-4BE7-B99C-58003F663F6AQ33869676-EF2C1D36-BCC3-4704-97FB-12DF09E97DE4Q33874055-91CA3303-D2EA-43EA-B1EB-960E7CDD78B3Q33891378-A06B1EAF-2668-47BB-8395-B0F0DE5F3F93Q33893898-39BD4042-CA8D-48B9-9044-52C6EE310DE9Q34158739-54D9F884-5C16-44E8-AA67-B0F65C250546Q34400473-4124C682-9A2B-4567-99E1-6512E39D0D43Q34438834-6711A013-8F49-46DA-991C-9F0A2C0F927DQ34622805-322C9348-0F35-4DED-822F-203545667B5CQ34623146-5F202ECA-8832-4B0B-8B8C-086E7EC7F1CCQ34640849-3A7E7000-8ADA-4963-B384-BB04371F71FCQ35017714-0657280D-F91A-4C49-AF7E-96D8C681AF58Q35025198-C56CF233-D72D-48DA-B692-C8625A40EEEDQ35036120-39E6E5E3-CD9C-48E6-AB1A-121A32A3BB18Q35100004-11503C36-00E4-4B70-8122-28FB6C7D0A74Q35166046-4E60374D-E88B-4413-B3DC-1824E9B0F714Q35277349-5957840C-F153-45B0-850C-99B5B3189310Q35531006-D3A13367-4263-4F56-AE01-216FD8C85300Q35536507-872B49BC-A3E2-4A89-A6C2-67BFE878FFABQ35644141-73434181-AC34-4AFC-942B-B48EC2A54D85
P2860
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Markers of bone turnover for t ...... rnational reference standards.
@en
Markers of bone turnover for t ...... rnational reference standards.
@nl
type
label
Markers of bone turnover for t ...... rnational reference standards.
@en
Markers of bone turnover for t ...... rnational reference standards.
@nl
prefLabel
Markers of bone turnover for t ...... rnational reference standards.
@en
Markers of bone turnover for t ...... rnational reference standards.
@nl
P2093
P50
P1476
Markers of bone turnover for t ...... ernational reference standards
@en
P2093
A Griesmacher
A J Foldes
H A Morris
IOF-IFCC Bone Marker Standards Working Group
S Silverman
S Vasikaran
P2888
P304
P356
10.1007/S00198-010-1501-1
P407
P577
2010-12-24T00:00:00Z